Art. -Nr.: HY-117200

Necrostatin-7

(Synonyms: Nec-7)

Kundenbewertung

Based on 1 Customer Validation

Necrostatin-7 (Nec-7) is a Necroptosis inhibitor with an EC₅₀ of 10.6 μM. Necrostatin-7 inhibits signal transduction from RANK to NFATc1 without affecting the activation of MAPK or NF-κB. Necrostatin-7 suppresses the expression levels of Acp5, Atp6v0d2, Ctsk and Dcstamp. Necrostatin-7 reduces myocardial infarction size, ameliorates adverse left ventricular remodeling, decreases myocardial wall stress, reduces the amount and length of scar tissue, and improves left ventricular function. Necrostatin-7 exerts cardioprotective effects in a rat model of permanent coronary artery occlusion. Necrostatin-7 can be used in research related to osteolytic bone diseases and myocardial infarction.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.64%
CAS. Nr.: 351062-08-3
Formel: C₁₆H₁₀FN₅OS₂
Molecular Weight:371.41

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Necrostatin-7 Chemical Structure

CAS. Nr.: 351062-08-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Cellular Effect

Cell Line	Type	Value	Description	References
Jurkat	EC₅₀	10.6 μM Compound: nec-7	Inhibition of TNF-alpha-induced necroptosis in FADD-deficient human Jurkat cells Inhibition of TNF-alpha-induced necroptosis in FADD-deficient human Jurkat cells	[PMID: 18768316]

In Vitro

Necrostatin-7 (0.1-3 μM; 3 days) dose-dependently inhibits M-CSF- and RANKL-induced osteoclast differentiation in primary bone marrow-derived macrophages at concentrations from 0.1 to 3 μM, with near-complete inhibition at 2 μM and 3 μM, without reducing BMM viability^[1].
Necrostatin-7 (1-3 μM; 5 days) dose-dependently inhibits osteoclastic bone resorption by primary bone marrow-derived macrophages at concentrations from 1 to 3 μM, with near-complete inhibition at 2 μM and 3 μM after 5 days of treatment^[1].
Necrostatin-7 (1-3 μM; 1-3 days) dose-dependently suppresses RANKL-induced expression of osteoclastogenic marker genes (Acp5, Atp6v0d2, Ctsk, Dcstamp) in primary bone marrow-derived macrophages at 1 μM and 3 μM over 1 to 3 days of differentiation^[1].
Necrostatin-7 (1-3 μM; 1-3 days) dose-dependently inhibits RANKL-induced NFATc1 autoamplification in primary bone marrow-derived macrophages at 1 μM and 3 μM over 1 to 3 days of differentiation, with near-complete suppression at 3 μM^[1].
Necrostatin-7 inhibits TNF-α-induced necroptosis in FADD-deficient human Jurkat T cells with an EC₅₀ of 10.6 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Necrostatin-7 (14.5 mg/kg; i.p.; single dose 1 hour prior to permanent coronary occlusion) exerts cardioprotective properties, reducing myocardial wall stress (evidenced by lower NT-proBNP levels) and myocardial remodeling (evidenced by 9.0% infarct size) in rats with permanent coronary occlusion-induced myocardial infarction^[3].
Pretreatment with necrostatin-7 (14.5 mg/kg; i.p.) reduces left ventricular scar tissue and scar length, and lowers plasma N-terminal pro-brain natriuretic peptide levels, indicating improved left ventricular function in rats with permanent coronary occlusion-induced myocardial infarction^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar rats (male)^[3]
Dosage:

14.5 mg/kg
Administration:

i.p.; single dose 1 hour prior to permanent coronary occlusion
Result:

Reduced serum NT-proBNP level to 0.2 ng/mL.
Reduced myocardial infarct size to 9.0%.
Reduced infarct length to 2.9 mm.

Animal Model:

strain not specified^[4]
Dosage:

14.5 mg/kg
Administration:

i.p.; single dose 60 minutes before coronary occlusion
Result:

Reduced the amount of scar tissue and scar length in the left ventricle.
Decreased plasma levels of N-terminal pro-brain natriuretic peptide.

Chemical Information

CAS. Nr. 351062-08-3
Appearance Solid
Molecular Weight 371.41
Formel C₁₆H₁₀FN₅OS₂
Color Light yellow to brown
SMILES

O=C1N(C2=NC=CS2)C(S/C1=C\C3=CNN=C3C4=CC=C(F)C=C4)=N
Synonyms

Nec-7
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 10 mg/mL (26.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6924 mL

13.4622 mL

26.9244 mL

5 mM

0.5385 mL

2.6924 mL

5.3849 mL

10 mM

0.2692 mL

1.3462 mL

2.6924 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Fuji H, et al. Necrostatin-7 suppresses RANK-NFATc1 signaling and attenuates macrophage to osteoclast differentiation. Biochemical and biophysical research communications. 2018 Sep 05;503(2):544-549. [Content Brief]

[2]. Zheng W, et al. Structure-activity relationship study of a novel necroptosis inhibitor, necrostatin-7. Bioorganic & medicinal chemistry letters. 2008 Sep 15;18(18):4932-5. [Content Brief]

[3]. Dmitriev Y, et al. Necrostatin 7 Limits Myocardial Infarct Size and Reduces Cardiac Remodeling After Permanent Coronary Occlusion in Rats[J]. Circulation, 2014, 130(suppl_2): A17348-A17348.

[4]. Dmitriev Y V, et al. CARDIOPROTFETIVE EFECTS OF NECROSTATIN-7 IN THE RAT MODEL OF PERMANENT CORONARY OCCLUSION[J]. Rossiiskii Fiziologicheskii Zhurnal Imeni IM Sechenova, 2015, 101(4): 408-414.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6924 mL	13.4622 mL	26.9244 mL	67.3111 mL
	5 mM	0.5385 mL	2.6924 mL	5.3849 mL	13.4622 mL
	10 mM	0.2692 mL	1.3462 mL	2.6924 mL	6.7311 mL
	15 mM	0.1795 mL	0.8975 mL	1.7950 mL	4.4874 mL
	20 mM	0.1346 mL	0.6731 mL	1.3462 mL	3.3656 mL
	25 mM	0.1077 mL	0.5385 mL	1.0770 mL	2.6924 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Necrostatin-7

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Anti-Cardiovascular Disease Compound Library

Osteogenesis Compound Library

Heterocyclic Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Necrostatin-7

Immunology/Inflammation Compound Library

NF-κB Signaling Compound Library

Anti-Aging Compound Library

Covalent Screening Library

Anti-Cardiovascular Disease Compound Library

Osteogenesis Compound Library

Heterocyclic Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Necrostatin-7 Related Classifications

HY-117200 Related Classifications